Clinical trial • Phase I • Immunology

LFD-200 for Rheumatoid arthritis | Moderate to severe rheumatoid arthritis

Phase I trial of LFD-200 for Rheumatoid arthritis | Moderate to severe rheumatoid arthritis. 136 participants.

Overview

Trial Therapeutic Area
Immunology
Trial Disease
Rheumatoid arthritis | Moderate to severe rheumatoid arthritis
Trial Stage
Phase I

Key dates

Initial CTIS Submission Date
23-09-2025
First CTIS Authorization Date
30-01-2026

Trial design

Phase I trial across 3 sites in Poland.

Single Multiple Or Escalation Dose Combined
Yes
Target Sample Size
136

Recruitment

Planned Sample Size
136
Recruitment Window Months
17

Geography

Total Number Of Sites
3
Total Number Of Participants
136

Poland

Earliest CTIS Part Ii Submission Date
22-12-2025
Latest Decision Or Authorization Date
30-01-2026
Processing Time Days
39
Number Of Sites
3
Number Of Participants
40

Sites

Site Name
Medicover Integrated Clinical Services Sp. z o.o.
Department Name
MICS Centrum Medyczne Toruń
Contact Person Name
Sławomir Jeka
Contact Person Email
s.jeka@wp.pl
Site Name
Klinika Reuma Park Sp. z o.o. S.K.
Department Name
Centrum Medyczne Reuma Park
Contact Person Name
Janusz Jaworski
Contact Person Email
januszjaworski@ymail.com
Site Name
Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicher
Department Name
Centrum Wsparcia Badań Klinicznych
Contact Person Name
Maria Maślińska
Contact Person Email
maria.maslinska@spartanska.pl

Sponsor

Primary sponsor

Full Name
Lifordi Immunotherapeutics Inc.
Organisation Type
Pharmaceutical company
Country Of Registered Address
United States

Investigational products

Investigational Product Name
LFD-200

Related trials

Other published trials that may interest you.